Tobacco's Big Week

The U.S. Food and Drug Administration is holding its Center for Tobacco Products meeting this week, and it could be a very important week for tobacco investors.

Height Securities analyst Stefanie Miller said Wednesday this week could mark the first steps in a decade-long transition in the tobacco industry.

“We think initial FDA actions on allowable nicotine levels in combustible cigarettes and other tobacco products will likely come at some point during 1Q2018 after yesterday's report by the National Academies provided Members of Congress concerned with the public health risks of tobacco products additional ammunition to force the FDA to release its long-awaited advanced notice of proposed rulemaking (ANPRM) on nicotine,” Miller said in a note.

She says Philip Morris International Inc. PM could be one of the early winners if the FDA ramps up regulations because of the company’s new line of IQOS products.

Jefferies’ Take

Jefferies analyst Owen Bennett on Jan. 19 upgraded Philip Morris and Altria Group Inc MO from Hold to Buy and said the shift to reduced-risk products and the potential for M&A in the space should drive stock outperformance among tobacco companies in 2018.

“Industry-wide catalysts include US CT guidance (suggestions not yet fully priced in, especially at MO; also sector-wide considerations of increased investment), the ANPRM on nicotine in the US (some downside likely; buy on the dip), Canadian litigation (concerns overdone but causing anxiety, especially at BAT), and possible heated tobacco approval in the US (big upside potential for first to market),” Bennett said.

Ratings And Targets

Tobacco investors will be watching to see how the FDA chooses to act this week as the tobacco companies try to stay relevant in profitable in an increasingly regulated market.

Jefferies has the following price targets and ratings for major tobacco stocks:

  • Altria-Buy rating, $81 target.
  • British American Tobacco PLC (ADR) BTI-Buy rating, $80 target.
  • Philip Morris-Buy rating, $124 target.

Related Links:

The First US-Listed Marijuana ETF Ignites Today

What Were Once Vices Are Now Dividends: A Sinful New ETF

Posted In: Height SecuritiesJefferiesOwen BennettStefanie MillertobaccoAnalyst ColorNewsHealth CarePrice TargetPoliticsFDATop StoriesAnalyst RatingsGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.